Abstract
The development of novel therapeutics is a complex process that increasingly relies on the exploration of genomic data. By analyzing large-scale genomic datasets, researchers can identify genetic variations, biomarkers, and molecular targets that play critical roles in disease progression. This article explores how genomic data, including whole-genome sequencing, transcriptomics, and proteomics, can be used to uncover new therapeutic targets and facilitate drug discovery. We also discuss the tools and technologies available for genomic data analysis, the challenges involved, and future directions for leveraging genomics in drug development..
All articles published in the American Journal of Bioinformatics (AJB) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Under this license, authors retain full copyright of their work and grant permission to anyone to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Conditions:
-
Attribution: Appropriate credit must be given to the original author(s) and the source, a link to the license must be provided, and any changes made must be indicated.
-
No additional restrictions: You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This open-access license ensures that scholarly work published in AJB is freely accessible and usable, promoting knowledge dissemination and academic collaboration worldw